• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用小干扰RNA-脂质复合物联合抑制FOSL-1和YAP可降低胰腺肿瘤的生长。

Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor.

作者信息

Diego-González Lara, Fernández-Carrera Andrea, Igea Ana, Martínez-Pérez Amparo, Real Oliveira M Elisabete C D, Gomes Andreia C, Guerra Carmen, Barbacid Mariano, González-Fernández África, Simón-Vázquez Rosana

机构信息

CINBIO, Universidade de Vigo, Immunology Group, 36310 Vigo, Spain.

Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain.

出版信息

Cancers (Basel). 2022 Jun 24;14(13):3102. doi: 10.3390/cancers14133102.

DOI:10.3390/cancers14133102
PMID:35804874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9265026/
Abstract

Pancreatic cancer evades most of the current therapies and there is an urgent need for new treatments that could efficiently eliminate this aggressive tumor, such as the blocking of routes driving cell proliferation. In this work, we propose the use of small interfering RNA (siRNA) to inhibit the combined expression of FOSL-1 and YAP, two signaling proteins related with tumor cell proliferation and survival. To improve the efficacy of cell transfection, DODAB:MO (1:2) liposomes were used as siRNA nanocarriers, forming a complex denominated siRNA-lipoplexes. Liposomes and lipoplexes (carrying two siRNA for each targeted protein, or the combination of four siRNAs) were physico-chemically and biologically characterized. They showed very good biocompatibility and stability. The efficient targeting of FOSL-1 and YAP expression at both mRNA and protein levels was first proved in vitro using mouse pancreatic tumoral cell lines (KRAS and p53 knockout), followed by in vivo studies using subcutaneous allografts on mice. The peri-tumoral injection of lipoplexes lead to a significant decrease in the tumor growth in both Athymic Nude-Foxn1 and C57BL/6 mice, mainly in those receiving the combination of four siRNAs, targeting both YAP and FOSL-1. These results open a new perspective to overcome the fast tumor progression in pancreatic cancer.

摘要

胰腺癌能逃避目前的大多数治疗方法,因此迫切需要能有效消除这种侵袭性肿瘤的新疗法,比如阻断驱动细胞增殖的途径。在这项研究中,我们提议使用小干扰RNA(siRNA)来抑制FOSL-1和YAP的联合表达,这两种信号蛋白与肿瘤细胞增殖和存活相关。为提高细胞转染效率,将二油酰基二甲基溴化铵:蛋黄卵磷脂(1:2)脂质体用作siRNA纳米载体,形成一种名为siRNA-脂质复合物的复合体。对脂质体和脂质复合物(针对每种靶向蛋白携带两种siRNA,或四种siRNA的组合)进行了物理化学和生物学特性表征。它们显示出非常好的生物相容性和稳定性。首先在体外使用小鼠胰腺肿瘤细胞系(KRAS和p53基因敲除)证明了在mRNA和蛋白质水平对FOSL-1和YAP表达的有效靶向,随后在小鼠身上使用皮下同种异体移植进行了体内研究。脂质复合物的瘤周注射导致无胸腺裸鼠和C57BL/6小鼠的肿瘤生长显著减少,主要是在那些接受靶向YAP和FOSL-1的四种siRNA组合的小鼠中。这些结果为克服胰腺癌快速的肿瘤进展开辟了新的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/e733040854df/cancers-14-03102-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/3f20f5757123/cancers-14-03102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/a90341e1a8f1/cancers-14-03102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/519e65172149/cancers-14-03102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/486ea151309c/cancers-14-03102-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/0548224399ef/cancers-14-03102-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/837d669bfbf2/cancers-14-03102-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/c557866d4978/cancers-14-03102-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/e733040854df/cancers-14-03102-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/3f20f5757123/cancers-14-03102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/a90341e1a8f1/cancers-14-03102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/519e65172149/cancers-14-03102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/486ea151309c/cancers-14-03102-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/0548224399ef/cancers-14-03102-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/837d669bfbf2/cancers-14-03102-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/c557866d4978/cancers-14-03102-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fca/9265026/e733040854df/cancers-14-03102-g008.jpg

相似文献

1
Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor.使用小干扰RNA-脂质复合物联合抑制FOSL-1和YAP可降低胰腺肿瘤的生长。
Cancers (Basel). 2022 Jun 24;14(13):3102. doi: 10.3390/cancers14133102.
2
Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells.用于将小干扰RNA递送至癌细胞的基于单油酸甘油酯的隐形纳米载体。
Acta Biomater. 2015 Oct;25:216-29. doi: 10.1016/j.actbio.2015.07.032. Epub 2015 Jul 29.
3
siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.通过阳离子脂质体全身注射将小干扰RNA递送至肺转移瘤。
J Liposome Res. 2015;25(4):279-86. doi: 10.3109/08982104.2014.992024. Epub 2015 Sep 4.
4
Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.阳离子胆固醇衍生物脂质体介导的小干扰 RNA 递送至肝脏。
J Liposome Res. 2017 Dec;27(4):264-273. doi: 10.1080/08982104.2016.1205599. Epub 2016 Jul 21.
5
PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.用于原发性渗出性淋巴瘤中BLIMP-1基因沉默的聚乙二醇化小干扰RNA脂质复合物:抗肿瘤活性的体外证据
Eur J Pharm Biopharm. 2016 Feb;99:7-17. doi: 10.1016/j.ejpb.2015.11.007. Epub 2015 Nov 25.
6
Reduced in vitro and in vivo toxicity of siRNA-lipoplexes with addition of polyglutamate.聚谷氨酸的添加降低了 siRNA-脂质体复合物的体外和体内毒性。
J Control Release. 2013 Jan 10;165(1):1-8. doi: 10.1016/j.jconrel.2012.10.018. Epub 2012 Nov 2.
7
Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.突变型 KRAS 下游的转录调节因子 YAP 对于胰腺导管腺癌的肿瘤进展是必需的。
Sci Signal. 2014 May 6;7(324):ra42. doi: 10.1126/scisignal.2005049.
8
A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.稳定质粒载体介导的 c-Src 基因 siRNA 沉默对人胰腺癌细胞增殖和血管生成的抑制作用研究。
Oncol Rep. 2012 Mar;27(3):628-36. doi: 10.3892/or.2011.1602. Epub 2011 Dec 21.
9
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.一种使用YAP和泛RAF抑制剂治疗KRAS突变型胰腺癌的联合策略。
Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30.
10
Effects of cationic lipids in cationic liposomes and disaccharides in the freeze-drying of siRNA lipoplexes on gene silencing in cells by reverse transfection.阳离子脂质体中的阳离子脂质和冻干保护剂二糖对反式转染细胞中 siRNA 脂质体复合物基因沉默的影响。
J Liposome Res. 2020 Sep;30(3):235-245. doi: 10.1080/08982104.2019.1630643. Epub 2019 Jul 5.

引用本文的文献

1
Advances and Prospects in the Treatment of Pancreatic Cancer.胰腺癌治疗的进展与展望。
Int J Nanomedicine. 2023 Jul 19;18:3973-3988. doi: 10.2147/IJN.S413496. eCollection 2023.
2
RAS-targeted cancer therapy: Advances in drugging specific mutations.RAS靶向癌症治疗:针对特定突变的药物研发进展
MedComm (2020). 2023 May 27;4(3):e285. doi: 10.1002/mco2.285. eCollection 2023 Jun.
3
Synovial Fluid Derived from Human Knee Osteoarthritis Increases the Viability of Human Adipose-Derived Stem Cells through Upregulation of FOSL1.

本文引用的文献

1
Narciclasine is a novel YAP inhibitor that disturbs interaction between YAP and TEAD4.水仙环素是一种新型的YAP抑制剂,它会干扰YAP与TEAD4之间的相互作用。
BBA Adv. 2021 Mar 27;1:100008. doi: 10.1016/j.bbadva.2021.100008. eCollection 2021.
2
New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting.胰腺癌新视角:虚拟会议纪要。
Gastroenterology. 2021 Sep;161(3):785-791. doi: 10.1053/j.gastro.2021.04.082. Epub 2021 Jun 2.
3
Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages.
滑膜液源自人类膝关节骨关节炎,通过上调 FOSL1 增加了人脂肪干细胞的活力。
Cells. 2023 Jan 15;12(2):330. doi: 10.3390/cells12020330.
胰腺癌的特征是补体高的血液单核细胞和肿瘤相关巨噬细胞。
Life Sci Alliance. 2021 Mar 29;4(6). doi: 10.26508/lsa.202000935. Print 2021 Jun.
4
Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways.机器学习和化学生物基因组学方法定义和预测 Hippo 和 MAPK 通路的串扰。
Cancer Discov. 2021 Mar;11(3):778-793. doi: 10.1158/2159-8290.CD-20-0706. Epub 2020 Nov 18.
5
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.胰腺癌的治疗抵抗:逆转治疗抵抗之路。
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188461. doi: 10.1016/j.bbcan.2020.188461. Epub 2020 Nov 4.
6
Assembly strategy of liposome and polymer systems for siRNA delivery.脂质体和聚合物系统用于 siRNA 递呈的组装策略。
Int J Pharm. 2021 Jan 5;592:120033. doi: 10.1016/j.ijpharm.2020.120033. Epub 2020 Nov 1.
7
Complement System: Promoter or Suppressor of Cancer Progression?补体系统:癌症进展的促进者还是抑制者?
Antibodies (Basel). 2020 Oct 25;9(4):57. doi: 10.3390/antib9040057.
8
YAP and AP-1 Cooperate to Initiate Pancreatic Cancer Development from Ductal Cells in Mice.YAP 和 AP-1 合作从小鼠的导管细胞起始胰腺癌的发生。
Cancer Res. 2020 Nov 1;80(21):4768-4779. doi: 10.1158/0008-5472.CAN-20-0907. Epub 2020 Sep 8.
9
Genome-wide cooperation of EMT transcription factor ZEB1 with YAP and AP-1 in breast cancer.EMT 转录因子 ZEB1 在乳腺癌中与 YAP 和 AP-1 的全基因组合作。
EMBO J. 2020 Sep 1;39(17):e103209. doi: 10.15252/embj.2019103209. Epub 2020 Jul 21.
10
Pancreatic cancer.胰腺癌。
Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0.